Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROSEMARIE SCHMANDT and KAREN H LU.
ROSEMARIE SCHMANDT
Connection Strength
2.527
KAREN H LU
  1. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011 Dec; 205(6):518-25.
    View in: PubMed
    Score: 0.394
  2. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel). 2020 Jan 02; 12(1).
    View in: PubMed
    Score: 0.178
  3. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila). 2018 08; 11(8):477-490.
    View in: PubMed
    Score: 0.159
  4. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer. 2017 06; 27(5):854-862.
    View in: PubMed
    Score: 0.149
  5. Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. Oncology. 2017; 92(2):109-114.
    View in: PubMed
    Score: 0.144
  6. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol. 2016 12 10; 34(35):4225-4230.
    View in: PubMed
    Score: 0.143
  7. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.143
  8. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer. 2014 Nov 15; 120(22):3457-68.
    View in: PubMed
    Score: 0.122
  9. CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecol Oncol. 2014 Apr; 133(1):83-9.
    View in: PubMed
    Score: 0.120
  10. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013 Dec; 12(12):2847-56.
    View in: PubMed
    Score: 0.116
  11. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 2013 Jul; 209(1):24.e1-24.e12.
    View in: PubMed
    Score: 0.111
  12. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
    View in: PubMed
    Score: 0.071
  13. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
    View in: PubMed
    Score: 0.062
  14. Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer. bioRxiv. 2024 Jun 11.
    View in: PubMed
    Score: 0.061
  15. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300.
    View in: PubMed
    Score: 0.060
  16. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52.
    View in: PubMed
    Score: 0.060
  17. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
    View in: PubMed
    Score: 0.057
  18. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul; 90(1):44-50.
    View in: PubMed
    Score: 0.057
  19. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol. 2003 Mar; 88(3):363-8.
    View in: PubMed
    Score: 0.055
  20. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release. 2021 11 10; 339:521-530.
    View in: PubMed
    Score: 0.050
  21. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun. 2020 07 15; 11(1):3546.
    View in: PubMed
    Score: 0.046
  22. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
    View in: PubMed
    Score: 0.045
  23. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29; 7:11150.
    View in: PubMed
    Score: 0.034
  24. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
    View in: PubMed
    Score: 0.030
  25. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012 Feb 01; 18(3):771-82.
    View in: PubMed
    Score: 0.026
  26. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007 Oct; 26(4):404-9.
    View in: PubMed
    Score: 0.019
  27. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 2003 Feb; 36(2):53-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.